[go: up one dir, main page]

WO2005060961A3 - Nouveau traitement du reflux gastrooesophagien pathologique - Google Patents

Nouveau traitement du reflux gastrooesophagien pathologique Download PDF

Info

Publication number
WO2005060961A3
WO2005060961A3 PCT/US2004/041133 US2004041133W WO2005060961A3 WO 2005060961 A3 WO2005060961 A3 WO 2005060961A3 US 2004041133 W US2004041133 W US 2004041133W WO 2005060961 A3 WO2005060961 A3 WO 2005060961A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastro
treatment
tlesrs
gerd
reflux disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041133
Other languages
English (en)
Other versions
WO2005060961A2 (fr
Inventor
Anders Lehmann
Jan Mattsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Shire NPS Pharmaceuticals Inc
Original Assignee
AstraZeneca AB
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, NPS Pharmaceuticals Inc filed Critical AstraZeneca AB
Publication of WO2005060961A2 publication Critical patent/WO2005060961A2/fr
Publication of WO2005060961A3 publication Critical patent/WO2005060961A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention a trait à l'utilisation d'un composé de formule (II) pour l'inhibition des relaxations transitoires du sphincter inférieur de l'oesophage. Dans un autre aspect, l'invention a trait à l'utilisation des composés de formule (II) pour le traitement du reflux gastrooesophagien pathologique.
PCT/US2004/041133 2003-12-18 2004-12-10 Nouveau traitement du reflux gastrooesophagien pathologique Ceased WO2005060961A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53023203P 2003-12-18 2003-12-18
US60/530,232 2003-12-18

Publications (2)

Publication Number Publication Date
WO2005060961A2 WO2005060961A2 (fr) 2005-07-07
WO2005060961A3 true WO2005060961A3 (fr) 2006-01-05

Family

ID=34710160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041133 Ceased WO2005060961A2 (fr) 2003-12-18 2004-12-10 Nouveau traitement du reflux gastrooesophagien pathologique

Country Status (1)

Country Link
WO (1) WO2005060961A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3103800T (pt) 2003-04-11 2018-07-27 Ptc Therapeutics Inc Compostos do ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e o tratamento de doenças
SG170819A1 (en) 2006-03-30 2011-05-30 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
KR102497273B1 (ko) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
CA3003132A1 (fr) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methodes de traitement de l'epilepsie

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053825A (fr) * 1963-03-22
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
EP0328200A1 (fr) * 1988-02-12 1989-08-16 Merck Sharp & Dohme Ltd. Systèmes cycliques à cinq chaînons substitués par des cycles azacycliques
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5627200A (en) * 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
EP0795328A1 (fr) * 1996-03-15 1997-09-17 Pfizer Inc. Utilisation de dérivés de naphtalène pour le traitement de cancer des poumons
WO2001012627A1 (fr) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisation en tant qu'antagonistes des recepteurs du glutamate metabotrope
WO2001085723A1 (fr) * 2000-05-08 2001-11-15 James Black Foundation Limited Ligands (ii) de recepteur de la gastrine et de la cholecystokinine
US6495578B1 (en) * 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
WO2002100826A2 (fr) * 2001-06-08 2002-12-19 Cytovia, Inc. 3-aryl-5-aryl-[1,2,4]-oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations
US20030055085A1 (en) * 1999-08-19 2003-03-20 Wagenen Bradford Van Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
WO2003061567A2 (fr) * 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
US20030158155A1 (en) * 2000-04-28 2003-08-21 Yozo Hori Mmp-12 inhibitors
WO2004000316A1 (fr) * 2002-06-20 2003-12-31 Astrazeneca Ab Emploi d'antagonistes de mglur5 pour le traitement du reflux gastro-oesophagien

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053825A (fr) * 1963-03-22
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
EP0328200A1 (fr) * 1988-02-12 1989-08-16 Merck Sharp & Dohme Ltd. Systèmes cycliques à cinq chaînons substitués par des cycles azacycliques
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5627200A (en) * 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
EP0795328A1 (fr) * 1996-03-15 1997-09-17 Pfizer Inc. Utilisation de dérivés de naphtalène pour le traitement de cancer des poumons
US6495578B1 (en) * 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
WO2001012627A1 (fr) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisation en tant qu'antagonistes des recepteurs du glutamate metabotrope
US20030055085A1 (en) * 1999-08-19 2003-03-20 Wagenen Bradford Van Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20030158155A1 (en) * 2000-04-28 2003-08-21 Yozo Hori Mmp-12 inhibitors
WO2001085723A1 (fr) * 2000-05-08 2001-11-15 James Black Foundation Limited Ligands (ii) de recepteur de la gastrine et de la cholecystokinine
WO2002100826A2 (fr) * 2001-06-08 2002-12-19 Cytovia, Inc. 3-aryl-5-aryl-[1,2,4]-oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
WO2003061567A2 (fr) * 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
WO2004000316A1 (fr) * 2002-06-20 2003-12-31 Astrazeneca Ab Emploi d'antagonistes de mglur5 pour le traitement du reflux gastro-oesophagien

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200339, Derwent World Patents Index; Class B05, AN 2003-421390, XP002324067 *
PANCECHOWSKA-KSEPKO D ET AL: "[Studies of pyrazine derivatives. XVII. Synthesis and the tuberculostatic activity of pyrazinyl-1,3,4-oxadiazole derivatives]", ACTA POLONIAE PHARMACEUTICA. 1986, vol. 43, no. 2, 1986, pages 116 - 123, XP008045320, ISSN: 0001-6837 *
PANCECHOWSKA-KSEPKO D ET AL: "[Studies of pyrazine derivatives. XX. Synthesis and tuberculostatic activity of 3-pyrazinol-1,2,4-oxadiazole derivatives]", ACTA POLONIAE PHARMACEUTICA. 1986, vol. 43, no. 3, 1986, pages 211 - 217, XP008045321, ISSN: 0001-6837 *

Also Published As

Publication number Publication date
WO2005060961A2 (fr) 2005-07-07

Similar Documents

Publication Publication Date Title
WO2005077373A3 (fr) Nouveau traitement du reflux gastro-oesophagien pathologique ii
WO2005077368A3 (fr) Nouveau traitement du reflux gastro-oesophagien pathologique iii
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2004014913A3 (fr) Inhibiteurs de la phosphodiesterase 4
HK1053831A1 (zh) 作为治疗药物的激酶抑制剂
EA200900934A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
WO2005061458A3 (fr) Inhibiteurs de la phosphodiesterase 4, notamment analogues de diarylamines n-substituees
AU2003229953A8 (en) Phthalazinone derivatives
WO2002072545A3 (fr) Composes de 9-aminoacyl tetracycline et procedes d'utilisation
NO20052378D0 (no) Pre-organiserte trisykliske integraseinhibitorforbindelser
WO2005074642A3 (fr) Composes chimiques
WO2004018457A8 (fr) Piperidine-phthalazones a substitution pyrrolidinedione utilises comme inhibiteurs de la phosphodiesterase-4 (pde4)
ATE275554T1 (de) Serinprotease-inhibitoren
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
WO2005060961A3 (fr) Nouveau traitement du reflux gastrooesophagien pathologique
PL377467A1 (pl) Aromatyczne związki jako środki przeciwzapalne, immunomodulujące i antyproliferacyjne
WO2004030664A3 (fr) Nouveaux composes pouvant inhiber une proliferation de cellules non desiree et leur utilisation
WO2005058841A3 (fr) Composes inhibiteurs de protease du vih
BR0200536A (pt) Compostos de sulfonilpiridazinana úteis como inibidores de aldose reductase
GEP20074140B (en) Novel method for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid and application of divalent salts of ranelic acid and the hydrates thereof in said synthesis
ATE358128T1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
SE0303491D0 (sv) New use VI
AU2003294275A8 (en) Compounds for inhibition of hiv infection by blocking hiv entry
SE0303490D0 (sv) New use V

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase